My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 99

    1.

    Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.

    Slama TG.

    Crit Care. 2008;12(5):233. Epub 2008 Oct 29. Review.PMID: 18983709 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparative review of the carbapenems.

    Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA.

    Drugs. 2007;67(7):1027-52. Review.PMID: 17488146 [PubMed - indexed for MEDLINE]Related articles

    3.

    Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

    Quale J, Bratu S, Gupta J, Landman D.

    Antimicrob Agents Chemother. 2006 May;50(5):1633-41.PMID: 16641429 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Current therapies for pseudomonas aeruginosa.

    Giamarellou H, Kanellakopoulou K.

    Crit Care Clin. 2008 Apr;24(2):261-78, viii. Review.PMID: 18361945 [PubMed - indexed for MEDLINE]Related articles

    5.

    Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.

    Pakyz AL, Oinonen M, Polk RE.

    Antimicrob Agents Chemother. 2009 May;53(5):1983-6. Epub 2009 Mar 9.PMID: 19273670 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.

    Poulakou G, Giamarellou H.

    Expert Opin Investig Drugs. 2008 May;17(5):749-71. Review.PMID: 18447600 [PubMed - indexed for MEDLINE]Related articles

    7.

    New developments in carbapenems.

    Kattan JN, Villegas MV, Quinn JP.

    Clin Microbiol Infect. 2008 Dec;14(12):1102-11. Review.PMID: 19076841 [PubMed - indexed for MEDLINE]Related articles

    8.

    Carbapenems: a potent class of antibiotics.

    Nicolau DP.

    Expert Opin Pharmacother. 2008 Jan;9(1):23-37. Review.PMID: 18076336 [PubMed - indexed for MEDLINE]Related articles

    9.

    Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.

    Matthews SJ, Lancaster JW.

    Clin Ther. 2009 Jan;31(1):42-63. Review.PMID: 19243706 [PubMed - indexed for MEDLINE]Related articles

    10.

    In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.

    Ohba F, Nakamura-Kamijo M, Watanabe N, Katsu K.

    Antimicrob Agents Chemother. 1997 Feb;41(2):298-307.PMID: 9021183 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.

    Zavascki AP, Soares FC, Superti SV, Silbert S, Silva FM, Barth AL.

    Int J Antimicrob Agents. 2007 Aug;30(2):187-9. Epub 2007 Apr 23. No abstract available. PMID: 17452093 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Antipseudomonal activity of carbapenem antibiotics]

    Sunagawa M, Kanazawa K, Nouda H.

    Jpn J Antibiot. 2000 Jul;53(7):479-511. Review. Japanese. PMID: 11019384 [PubMed - indexed for MEDLINE]Related articles

    13.

    [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory]

    Sumitani Y, Kobayashi Y.

    Jpn J Antibiot. 2007 Dec;60(6):394-403. Japanese. PMID: 18447209 [PubMed - indexed for MEDLINE]Related articles

    14.

    Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.

    Gelfand MS, Cleveland KO, Mazumder SA.

    J Antimicrob Chemother. 2009 Jun;63(6):1297-9. Epub 2009 Apr 15. No abstract available. PMID: 19369268 [PubMed - indexed for MEDLINE]Related articles

    15.

    In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.

    Shibata K, Adachi Y, Kato E, Nagano R, Fuse A, Hashizume T, Ohtake N, Okamoto O, Nakagawa S.

    J Antibiot (Tokyo). 1997 Feb;50(2):135-8.PMID: 9099222 [PubMed - indexed for MEDLINE]Related articles

    16.

    Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.

    Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A.

    J Infect Chemother. 2007 Jun;13(3):147-50. Epub 2007 Jun 21.PMID: 17593500 [PubMed - indexed for MEDLINE]Related articles

    17.

    Doripenem.

    Paterson DL, Depestel DD.

    Clin Infect Dis. 2009 Jul 15;49(2):291-8. Review.PMID: 19527173 [PubMed - indexed for MEDLINE]Related articles

    18.

    Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.

    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.

    APMIS. 2005 Mar;113(3):187-96.PMID: 15799762 [PubMed - indexed for MEDLINE]Related articles

    19.

    Doripenem: a new carbapenem in the treatment of nosocomial infection.

    Mandell L.

    Clin Infect Dis. 2009 Aug 15;49 Suppl 1:S1-3. Review.PMID: 19619016 [PubMed - indexed for MEDLINE]Related articles

    20.

    Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa.

    Rice LB.

    Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S100-5. Review.PMID: 16894511 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity